Newport Beach, CA (PRWEB) May 02, 2013
CDX Diagnostics, Inc (“CDX”) and Shared Medical Resources, LLC (“SMR”), filed a patent infringement action against Histologics, LLC, Poplar HealthCare, PLLC d/b/a Women’s Health Laboratories and Mattison Pathology, LLP d/b/a Avero Diagnostics (collectively, “Defendants”) in the United States District Court for the Southern District of New York. According to court documents, CDX and SMR allege, "the Defendants willfully infringe United States Patent No. 6,258,044 (“the ‘044 Patent”). The ‘044 patent is titled: “Apparatus and Method for Obtaining Transepithelial Specimen of a Body Surface Using a Non-Lacerating Technique.” (CDX Diagnostics, Inc. et al. v Histologics, LLC et al., no. 13 CIV 2795)"
Court documents also state, "CDX and SMR allege that Defendants have infringed and continue to infringe the ‘044 Patent by making, using, selling, and offering for sale at least, Histologics’ Soft-ECC and SoftBiopsy devices. CDX and SMR have not licensed Defendants to practice the ’044 Patent, and Defendants have no right or authority to practice or license others to practice the inventions claimed in the ’044 Patent (CDX Diagnostics, Inc. et al. v Histologics, LLC et al., no. 13 CIV 2795)."
CDX and SMR seek the full remedy and damages allowed by law, against the Defendants and all persons acting in active concert or participation with them who have allegedly infringed on the ‘044 Patent.
CDX and SMR have pioneered the development of minimally invasive biopsy brushes. SMR is the sole developer, manufacturer and distributor of the SpiraBrush CX, the only FDA-cleared, minimally invasive and patient-friendly cervical biopsy device. SMR has revolutionized minimally invasive cervical cancer screening providing a better patient experience.
David A Olsen, Chief Operating Officer